Project Grant HT94252510685
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$591K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
This Project Grant award of $590,625.00 from the U.S. Department of Defense's Military Medical Research and Development (CFDA 12.420) program supports a pilot study at the University of California, Los Angeles (UCLA) to investigate the use of dual immunotherapy (PD1/CD73) in combination with chemotherapy for treating patients with pancreatic adenocarcinoma. The study aims to elucidate the immune mechanisms of resistance to this treatment approach. The award has a performance period from...
This Project Grant award of $405,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Panorama Research Incorporated, a for-profit biotech company in Sunnyvale, California. The award aims to develop novel immunotherapies that target dual cancer-specific antigens for the treatment of advanced ovarian cancer. The research project will utilize a safe and controlled immune booster to enhance the efficacy of these targeted...
The Defense Health Agency awarded a $828,591 Project Grant under CFDA 12.420, the Military Medical Research and Development program, to Duke University. The grant supports research titled "Targeting the Tumor Microenvironment to Enhance Immunotherapy for SCLC", with a performance period from May 1, 2025 to April 30, 2027. This research aims to transform healthcare for military service members, veterans, and the public by advancing innovative biomedical investigations focused on...
The Defense Health Agency awarded a $602,814 Project Grant to the University of Nebraska Medical Center (UNMC) under the Military Medical Research and Development program (CFDA 12.420). The grant, with a performance period from November 1, 2024 to October 31, 2027, supports research to investigate "Targeting Extracellular Nucleoside Metabolism as a Strategy to Potentiate the Effects of Immunotherapy in Pancreatic Ductal Adenocarcinoma." The project aims to explore innovative approaches...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This federal Project Grant award of $610,059.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by The Johns Hopkins University to investigate "The Aging Microenvironment as a Driver of Pancreatic Cancer Metastasis." The award has a performance period from July 1, 2025 to June 30, 2028 and aims to transform healthcare for military service members, veterans, and the general public through innovative biomedical...
The Department of Defense's Defense Health Agency awarded a $558,832 Project Grant to Tufts University School of Medicine under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2024. This grant will support research focused on "Targeting Differentiation Epitope in CD11b of Tumor-Associated Inflammatory Monocytes: A Novel Adjuvant Dendritic Cell Therapy Approach for Mucosal Melanoma." The research aims to develop an innovative dendritic cell-based...